[ET Net News Agency, 22 March 2018] Credit Suisse lifted its target price for China
Medical System Holdings (CMS)(00867) to HK$23.3 from HK$22.2, and maintained its
"outperform" rating.
The research house said CMS delivered mixed results in product sales. Strong sales
growth was seen in major key products, including Ursofalk/Salofalk/Bioflor/Stulln, while
pressure came from sales of Deanxit/DanShenTong/NuoDiKang due to policy headwinds.
The result of blinded clinical trials of Traumakine for treating ARDS will be announced
in April. Credit Suisse raised its EPS forecasts of FY2018/19 by 2.2%/2.6% to reflect the
continuous growth of key products. (KL)